[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"overweight\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:overweight":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,132,0,25,[9,45,65,87,112,134,159,190,211,241,267,288,309,340,363,382,402,421,440,474,502,520,549,578,605],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100623096","phase-3-a-study-of-eloralintide-ly3841136-in-participants-with-persistent-obesity-who-are-treated-with-a-weekly-incretin-100623096",false,"NCT07392190","A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin","A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Persistent Obesity or Overweight Treated With a Weekly Incretin, With and Without Type 2 Diabetes","ENLIGHTEN-6","Inclusion Criteria:\n\n* Are on stable incretin therapy at screening\n* With persistent obesity or overweight defined as:\n\n  * ≥30 kg\u002Fm2 OR\n  * ≥27 kg\u002Fm2 with at least one existing obesity related complication at screening:\n\n    * hypertension\n    * dyslipidemia\n    * obstructive sleep apnea\n    * cardiovascular disease (for example, ischemic cardiovascular disease, New York Heart Association Functional Class I-III heart failure), or\n    * type 2 diabetes\n* Have a stable body weight (\\\u003C5% body weight change) at screening\n\nExclusion Criteria:\n\n* Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed \\>1 year before screening)\n* Have a prior or planned endoscopic procedure and\u002For device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)\n* Have type 1 diabetes\n* Have taken any of the following antihyperglycemic medications within 90 days before screening:\n\n  * dipeptidyl peptidase-4 (DPP-4) inhibitors\n  * amylin analogs\n  * insulin\n* Have had within 90 days prior to screening:\n\n  * heart attack\n  * stroke\n  * coronary artery revascularization\n  * unstable angina, or\n  * hospitalization due to congestive heart failure\n* Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure","ALL","18 Years",{"count":21,"type":22},900,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background therapy.\n\nParticipation in the study will last about 80 weeks.",[28,29],"Overweight","Obesity",[31],"Amylin receptor agonist","RECRUITING","2026-08-20",{"date":35,"type":36},"2026-08-21","ACTUAL",{"date":38,"type":36},"2026-02-10",{"date":40,"type":22},"2028-07",{"name":42,"class":43},"Eli Lilly and Company","INDUSTRY",187,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":23,"phases":55,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":58,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":64},"100617689","phase-3-a-study-of-eloralintide-ly3841136-in-participants-with-obesity-or-overweight-without-type-2-diabetes-100617689","NCT07321886","A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes","A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Obesity or Overweight, Without Type 2 Diabetes","ENLIGHTEN-1","Inclusion Criteria:\n\n* Have Body Mass Index (BMI) at screening of the following:\n\n  * 30 kilogram per square meter (kg\u002Fm2) OR\n  * 27 kg\u002Fm2 with at least one of the following weight-related health conditions at screening:\n\n    * high blood pressure\n    * dyslipidemia\n    * obstructive sleep apnea, or\n    * heart disease\n* Have a stable body weight (\\\u003C5% body weight change) for 90 days prior to screening.\n* Have a history of at least one self-reported unsuccessful dietary effort to reduce body weight\n\nExclusion Criteria:\n\n* Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed \\>1 year before screening)\n* Have a prior or planned endoscopic procedure and\u002For device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)\n* Have type 1 diabetes or type 2 diabetes\n* Have had within 90 days prior to screening:\n\n  * heart attack\n  * stroke\n  * coronary artery revascularization\n  * unstable angina, or\n  * hospitalization due to congestive heart failure\n* Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure\n* Have taken medications or alternative remedies intended for weight loss within 90 days of screening",{"count":54,"type":22},1980,[25],"The purpose of this study is to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight who do not have type 2 diabetes. The study has two phases: a main phase and an extension phase.\n\nParticipation in the main phase of the study will last about 75 weeks. Participants with prediabetes will continue in the extension phase for another 2 years.",[29,28],{"date":35,"type":36},{"date":60,"type":36},"2026-02-06",{"date":62,"type":22},"2030-07",{"name":42,"class":43},162,{"id":66,"slug":67,"hasResults":12,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":73,"targetDuration":4,"studyType":23,"phases":75,"briefSummary":76,"conditions":77,"keywords":78,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":80,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},"100614669","phase-3-a-study-of-eloralintide-ly3841136-in-participants-with-obesity-or-overweight-and-type-2-diabetes-100614669","NCT07282600","A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes","A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Obesity or Overweight, and Type 2 Diabetes","ENLIGHTEN-2","Inclusion Criteria:\n\n* Have type 2 diabetes\n* Are on stable treatment for type 2 diabetes for at least 90 days prior to screening\n* Have a BMI ≥ 27 kg\u002Fm2\n* Have a stable body weight (\\\u003C5% body weight change) for 90 days prior to screening\n\nExclusion Criteria:\n\n* Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed \\>1 year before screening)\n* Have a prior or planned endoscopic procedure and\u002For device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)\n* Have type 1 diabetes\n* Have taken any of the following antihyperglycemic medications within 90 days before screening:\n\n  * amylin analogs\n  * glucagon-like peptide-1 (GLP-1) receptor agonists\n  * glucose-dependent insulinotropic polypeptide\u002Fglucagon-like peptide-1 (GIP\u002FGLP) receptor agonists, or\n  * insulin\n* Have had within 90 days prior to screening:\n\n  * heart attack\n  * stroke\n  * coronary artery revascularization\n  * unstable angina, or\n  * hospitalization due to congestive heart failure\n* Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure\n* Have taken medications or alternative remedies intended for weight loss within 90 days of screening",{"count":74,"type":22},1035,[25],"The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants with overweight or obesity and type 2 diabetes. Participation in the study will last about 75 weeks.",[28,29],[79],"Type 2 Diabetes",{"date":35,"type":36},{"date":82,"type":36},"2025-12-15",{"date":84,"type":22},"2028-02",{"name":42,"class":43},159,{"id":88,"slug":89,"hasResults":12,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":94,"enrollmentInfo":95,"targetDuration":4,"studyType":23,"phases":97,"briefSummary":99,"conditions":100,"keywords":102,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":105,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":111},"100609513","phase-2-a-study-of-macupatide-ly3532226-and-eloralintide-ly3841136-alone-or-in-combination-in-adults-with-obesity-or-overweight-and-with-type-2-diabetes-100609513","NCT07215559","A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes","A Phase 2, Parallel-Group, Double-Blind, Placebo-Controlled Study to Investigate Weight Reduction With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight and With Type 2 Diabetes","Inclusion Criteria:\n\n* Have type 2 diabetes\n* Have an HbA1c ≥7.5% to ≤10.5% at screening\n* Have been treated with any of the following, alone or in combination, for at least 3 months prior to screening\n\n  * Diet and exercise\n  * Stable dose of metformin\n  * Sodium-glucose cotransporter-2 (SGLT2) inhibitor\n* Have had a stable body weight (\\\u003C5% body weight gain and\u002For loss) for the 3 months prior to screening\n* Have a BMI of 27 or greater at screening\n\nExclusion Criteria:\n\n* Have any form of diabetes other than type 2 diabetes\n* Have a prior or planned surgical treatment for obesity, except prior liposuction or abdominoplasty, if performed \\>1 year prior to screening\n* Have any of the following cardiovascular conditions within 3 months prior to screening:\n\n  * acute myocardial infarction\n  * cerebrovascular accident (stroke)\n  * unstable angina, or\n  * hospitalization due to congestive heart failure\n* Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years, exceptions include\n\n  * basal or squamous cell skin cancer\n  * in situ carcinomas of the cervix, or\n  * in situ prostate cancer\n* Have been prescribed any of the following receptor agonists (RA) or their combination for any indication within the last 6 months:\n\n  * amylin RA\n  * dual amylin and calcitonin RA\n  * glucagon-like peptide-1 receptor (GLP-1) RA\n  * glucose-dependent insulinotropic peptide (GIP)\u002FGLP-1 RA\n  * GLP-1\u002Fglucagon (GCG) RAs, or\n  * GIP\u002FGLP-1\u002FGCG RAs\n* Have used excluded antihyperglycemic medications within 3 months prior to screening (including, but not limited to, sulfonylureas, dipeptidyl peptidase-4 inhibitors, alpha-glucosidase inhibitors, thiazolidinediones, and meglitinides\n* Have used insulin for diabetic control within the prior year (short term use in certain situations allowed","75 Years",{"count":96,"type":22},200,[98],"PHASE2","The purpose of this study is to investigate weight reduction with macupatide and eloralintide, alone or in combination, in adult participants with obesity or overweight and with type 2 diabetes. Participation in the study will last about 48 weeks.",[29,28,101],"Diabetes Mellitus, Type 2",[103,104],"GIP","Amylin",{"date":35,"type":36},{"date":107,"type":36},"2025-10-16",{"date":109,"type":22},"2027-05",{"name":42,"class":43},42,{"id":113,"slug":114,"hasResults":12,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":119,"enrollmentInfo":120,"targetDuration":4,"studyType":23,"phases":122,"briefSummary":123,"conditions":124,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":133},"100644100","phase-2-a-study-to-test-whether-bi-3034701-helps-people-to-lose-weight-who-live-with-obesity-or-overweight-100644100","NCT07662122","A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight","A Phase II, Randomised, Double-blind, Parallel-group, 42-week Dose-finding Trial for BI 3034701 Administered Subcutaneously Compared to Placebo in Participants With Obesity or Overweight","Inclusion criteria:\n\n1. Male or female, age ≥18 to \\\u003C75 years at the time of signing informed consent, and at least the legal age of consent in countries where it is \\>18 years\n2. Body mass index (BMI) ≥30 kg\u002Fm² at screening, OR BMI ≥27 kg\u002Fm² at screening with the presence of at least 1 weight-related complication.\n3. History of at least one self-reported unsuccessful dietary effort to lose body weight\n4. Signed and dated written informed consent in accordance with International Conference on Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial. Persons must be capable of giving informed consent independently\n5. Women of childbearing potential (WOCBP) must be ready and able to use highly effective methods of birth control per International Conference on Harmonisation (ICH) M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria and instructions on the duration of their use will be provided in the participant information sheet and in protocol.\n6. In the investigator's opinion, participants are well-motivated, capable, and willing to: Sign the informed consent form (ICF); Learn how to self-inject the investigational medicinal product (IMP)(s) in the abdomen as required for this protocol (persons with physical limitations who are not able to perform the injections must have the assistance of an individual trained to inject the IMP(s)) OR Inject the IMP or accept injection from a designated person; Follow study procedures for the duration of the study, including, but not limited to: follow lifestyle advice (for example, dietary restrictions and physical activity plan), maintain diaries, complete required questionnaires, and handle the IMP(s) as described in the instructions for use (IFU)\n\nExclusion criteria:\n\n1. Body weight increase or decrease (self-reported) of greater than 5% in the 3 months prior to screening\n2. Treatment with anti-obesity medication and\u002For body weight change-inducing medication within 3 months before screening\n3. Prior surgery of the gastrointestinal (GI) tract that could interfere with body weight including minimally invasive\u002Fendoscopic bariatric devices and any bariatric or metabolic surgery involving resection, sleeve gastrectomy, or bypass procedures (e.g. Roux-en-Y, one-anastomosis gastric bypass, duodenal-jejunal bypass sleeve), regardless of whether the device or bypass was removed. The following are allowed: (1) liposuction and\u002For abdominoplasty, if performed \\>1 year before screening, (2) lap banding, if the band has been removed \\>1 year before screening, (3) intragastric balloon, if the balloon has been removed \\>1 year before screening\n4. Have obesity induced by other endocrinologic disorders (for example, Cushing Syndrome) or diagnosed monogenetic or syndromic forms of obesity (for example, melanocortin 4 receptor deficiency, leptin deficiency, or Prader Willi Syndrome)\n5. A Haemoglobin A1c (HbA1c) ≥6.5% (≥48 mmol\u002Fmol) as measured by the central laboratory at screening\n6. History of type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM) or treatment with glucose-lowering agent starting within 3 months before screening\n7. Use of glucagon-like-peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), glucagon receptor (GCGR) or neuropeptide Y receptor 2 (NPY2R) agonists (or the combinations thereof) within 3 months before screening\n8. Answered \"yes\" to any of the suicide-related behaviours (actual attempt, interrupted attempt, aborted attempt, preparatory act or behaviour) or to the non-suicidal self-injurious behaviour question on the \"Suicidal Behaviour\" section of the Columbia-Suicide Severity Rating Scale (C-SSRS) related to the past 2 years before screening visit up to and including the randomisation visit Further exclusion criteria apply.","74 Years",{"count":121,"type":22},300,[98],"This study is open to adults between 18 and 74 years of age and who have a body mass index (BMI) of 30 kg\u002Fm2 or more, or a BMI of 27 kg\u002Fm2 or more and at least 1 health problem related to their weight. People who have previously not managed to lose weight by changing their diet can participate. People with type 2 diabetes cannot take part in this study.\n\nThe purpose of this study is to find out whether a medicine called BI 3034701 helps people living with obesity or overweight to lose weight. This study has 7 groups of participants. Groups 1 to 6 get different doses of BI 3034701; Group 7 gets placebo. Placebo looks like BI 3034701 but does not contain any medicine. Every participant has more than an 80% chance of getting BI 3034701. Participants receive 2 injections of BI 3034701 or placebo under their skin for 42 weeks. In addition to the study medicine, all participants receive counselling to make changes to their diet and to exercise regularly.\n\nParticipants are in the study for about 10 months. During this time, they visit the study site 15 times. The study doctors regularly measure the participants' body weight and take necessary laboratory tests. Participants also answer questions about their well-being and note their food intake and physical activity in diaries. The results will be compared between groups of participants to see whether the treatment works. The study doctors also regularly check participants' health and take note of any unwanted effects.",[29,28],"2026-08-19",{"date":33,"type":36},{"date":128,"type":36},"2026-06-30",{"date":130,"type":22},"2027-08-18",{"name":132,"class":43},"Boehringer Ingelheim",55,{"id":135,"slug":136,"hasResults":12,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":141,"sex":18,"minAge":19,"maxAge":142,"enrollmentInfo":143,"targetDuration":4,"studyType":23,"phases":145,"briefSummary":147,"conditions":148,"keywords":149,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":158},"100649815","phase-1-a-study-of-eloralintide-ly3841136-in-participants-with-obesity-or-overweight-100649815","NCT07738614","A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight","A Phase 1, Investigator- and Participant-Blinded, Placebo-Controlled, Randomized, Multiple-Dose Study to Evaluate the Gastric Emptying Delay, Pharmacokinetics, Safety, and Tolerability of Eloralintide in Participants With Obesity or Overweight","Inclusion Criteria:\n\n* Have overweight or obesity, but are otherwise overtly healthy.\n* Have a body mass index (BMI) within the range of 27.0 to 45.0 kilograms (kg)\u002Fsquare meter (m²), inclusive.\n* Have had a stable body weight, with less than 5 percent (%) change during the 3-month period prior to screening.\n\nExclusion Criteria:\n\n* Have been diagnosed with Type 1 or Type 2 diabetes mellitus, or have either of the following at screening\n\n  * A fasting plasma glucose concentration greater than or equal to 126 milligrams (mg)\u002Fdeciliter (dL) or 7.0 millimoles (mmol)\u002Fliter (L), or\n  * Hemoglobin A1C (HbA1c) greater than or equal to 6.5% or 48 mmol\u002Fmole (mol).\n* Have a history or presence of psychiatric disorders, including a history of major depressive disorder or severe psychiatric disorders such as schizophrenia, and bipolar disorder, within the last 2 years.\n* Have received a glucagon-like peptide-1 (GLP-1) receptor agonist, glucose-dependent insulinotropic polypeptide (GIP)\u002FGLP-1 receptor agonist, or GIP\u002FGLP-1\u002Fglucagon receptor agonist within 60 days or 5 half-lives, whichever is longer, prior to screening.\n* Are in the judgment of the investigator, actively suicidal or deemed to be at significant risk for suicide.",true,"65 Years",{"count":144,"type":22},56,[146],"PHASE1","The main purpose of this study is to find out how significantly Eloralintide slows stomach emptying in participants who are overweight or obese. For each participant, the study will last approximately 21 weeks and will include 2 overnight stays in the clinical research unit (CRU) lasting between 4 and 8 days. There will be 13 other visits.",[29,28],[150],"Healthy","2026-08-18",{"date":33,"type":36},{"date":154,"type":36},"2026-07-31",{"date":156,"type":22},"2026-12",{"name":42,"class":43},2,{"id":160,"slug":161,"hasResults":12,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":165,"eligibilityCriteria":166,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":23,"phases":169,"briefSummary":170,"conditions":171,"keywords":172,"overallStatus":180,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":189},"100652683","phase-3-a-study-to-investigate-the-efficacy-and-safety-of-elecoglipron-in-asian-participants-with-obesity-or-overweight-with-or-without-type-2-diabetes-mellitus-100652683","NCT07775404","A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus","A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre Study to Evaluate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus (EMBOLD-Asia)","Elecoglipron","Inclusion Criteria:\n\n* Adult participant aged 18 years or older at the time of informed consent.\n* Body mass index (BMI) at screening of:\n* 28 kg\u002Fm\\^2 or higher, or\n* 24 kg\u002Fm\\^2 to less than 28 kg\u002Fm\\^2 with at least 1 weight-related comorbidity.\n* Stable body weight (self-reported or documented) for 90 days prior to the screening visit (± 5% body weight change)\n* History of at least 1 self-reported unsuccessful dietary effort to lose body weight.\n* Participants with type 2 diabetes mellitus, if enrolled, and have HbA1c from 6.5% to less than 10.0% at screening.\n\nExclusion Criteria:\n\n* Any of the following medical history, laboratory values, or complications related to diabetes:\n* T1DM\n* HbA1c ≥ 10% (86 mmol\u002Fmol) at the screening visit\n* Currently receiving, or anticipated to receive, therapeutic intervention for diabetic retinopathy and\u002For macular edema.\n* Have had more than one episode of severe hypoglycemia within 180 days prior to the screening visit, or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms.\n* History of acute (unless due to previously resolved gallstone pancreatitis and post-cholecystectomy) or chronic pancreatitis.\n* History\u002Ffamily history (first degree biologic relatives) of medullary thyroid cancer or multiple endocrine neoplasia type 2.",{"count":168,"type":22},351,[25],"The purpose of this study is to evaluate the efficacy and safety of elecoglipron compared with placebo adjunct to diet and exercise for weight management, in adult participants living with obesity or overweight with or without T2DM.",[29,28],[173,174,175,176,177,178,179],"elecoglipron","AZD5004","ECC5004","GLP-1 receptor agonist","Weight loss","Weight management","Type 2 diabetes mellitus","NOT_YET_RECRUITING","2026-08-17",{"date":33,"type":36},{"date":184,"type":22},"2026-08-28",{"date":186,"type":22},"2028-04-20",{"name":188,"class":43},"AstraZeneca",49,{"id":191,"slug":192,"hasResults":12,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":4,"eligibilityCriteria":196,"healthyVolunteers":141,"sex":18,"minAge":19,"maxAge":142,"enrollmentInfo":197,"targetDuration":4,"studyType":23,"phases":199,"briefSummary":200,"conditions":201,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":210},"100647600","phase-1-a-research-study-on-how-ubt251-affects-levels-of-midazolam-caffeine-and-warfarin-in-the-blood-of-participants-with-excess-body-weight-100647600","NCT07710768","A Research Study on How UBT251 Affects Levels of Midazolam, Caffeine and Warfarin in the Blood of Participants With Excess Body Weight","An Open-label, Single-sequence, Crossover Study Investigating the Influence of UBT251 on Pharmacokinetics of Index Substrates for Cytochrome P450 Enzymes in Participants With Overweight or Obesity","Inclusion Criteria:\n\n* Male or female (sex assigned at birth, inclusive of all gender identities).\n* Age 18-65 years (both inclusive) at the time of signing the informed consent.\n* BMI between 27.0-39.9 kg\u002Fm\\^2 (both inclusive) at screening. Overweight should be due to excess adipose tissue, as judged by the investigator.\n* Body weight \\>=60.0 kg.\n* Considered to be generally healthy, except for overweight or obesity, based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator.\n\nExclusion Criteria:\n\n* Known or suspected hypersensitivity to study intervention(s) or related products.\n* Treatment with any marketed product containing compounds with glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), or glucagon (GCG) receptor agonism within 90 days before screening.\n* Use of prescription medicinal products or non-prescription drugs, including any herbal medicine known to interfere with the metabolic CYP pathways, such as perikon (St. John's Wort), ginseng, garlic, milk thistle, and echinaceae, within 14 days (or within 5 half-lives of the medicinal product, whichever is longest) of screening, with the exception of use of routine vitamins (vitamins used within a normal dose reference interval), occasional use of acetaminophen, ibuprofen, or topical medication not reaching systemic circulation.\n* Any contraindications for the use of caffeine, midazolam, and warfarin used in the study according to Vivarin®, Midazolam®, and warfarin sodium product information.\n* Presence of clinically significant gastrointestinal disorders or symptoms of gastrointestinal disorders potentially affecting absorption of drugs or nutrients, or as judged by the investigator.\n* History of major surgical procedures involving the stomach potentially affecting absorption of trial products (e.g. subtotal and total gastrectomy, sleeve gastrectomy, gastric bypass surgery) or current presence of gastrointestinal implant.",{"count":198,"type":22},44,[146],"The purpose of this clinical study is to find out if UBT251 is safe and effective to be taken together with medicines, like midazolam, caffeine and warfarin in participants living with overweight or obesity.",[29,28],"2026-08-14",{"date":151,"type":36},{"date":205,"type":36},"2026-07-15",{"date":207,"type":22},"2027-04-07",{"name":209,"class":43},"Novo Nordisk A\u002FS",1,{"id":212,"slug":213,"hasResults":12,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":217,"eligibilityCriteria":218,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":219,"targetDuration":4,"studyType":23,"phases":221,"briefSummary":222,"conditions":223,"keywords":230,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":233,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":240},"100642828","phase-2-a-study-of-pf-08653945-and-pf-08653944-in-adults-with-overweight-or-obesity-solis-1-100642828","NCT07575932","A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity (SOLIS-1)","A PHASE 2B, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, DOSE RANGING, DOSE-FINDING, UMBRELLA STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-08653945 AND PF-08653944, ALONE OR IN COMBINATION, IN ADULTS WITH OVERWEIGHT OR OBESITY (SOLIS-1)","SOLIS-1","Inclusion Criteria:\n\nEligible participants for this study include:\n\n* adults aged 18 years or older with\n* obesity (BMI of 30.0 kg\u002Fm2 to 50.0 kg\u002Fm2) or with\n* overweight (BMI of 27.0 kg\u002Fm2 to \\\u003C30.0 kg\u002Fm2) who also have at least 1 prespecified weight-related comorbidity (hypertension, dyslipidemia, cardiovascular disease, or obstructive sleep apnea), at the screening visit.\n\nExclusion Criteria:\n\nParticipants who are not eligible include those with diabetes mellitus, a body weight change of \\>5% or use of weight loss medications in the 12 weeks prior to screening, a history of or plan for surgical treatment for obesity, and those who are unable or unwilling to comply with contraceptive requirements or are pregnant or lactating.",{"count":220,"type":22},872,[98],"This study is being done to learn about the safety and effects of the study drugs, PF-08653945 and PF-08653944, when given alone or together for weight loss, compared to a placebo (a dummy drug that has no active ingredient in it).",[28,29,224,225,226,227,228,229],"Overweight and\u002For Obesity","Overweight or Obesity","Overnutrition","Nutrition Disorders","Nutritional and Metabolic Diseases","Body Weight",[226,227,228,229,29,28,231,104,232],"GLP-1RA","DACRA",{"date":181,"type":36},{"date":235,"type":36},"2026-05-11",{"date":237,"type":22},"2028-01-05",{"name":239,"class":43},"Pfizer",65,{"id":242,"slug":243,"hasResults":12,"nctId":244,"briefTitle":245,"officialTitle":246,"acronym":4,"eligibilityCriteria":247,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":248,"targetDuration":4,"studyType":23,"phases":250,"briefSummary":251,"conditions":252,"keywords":253,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":260,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":266},"100639041","phase-3-a-study-to-learn-about-the-study-medicine-called-berobenatide-pf-08653944-in-people-with-overweight-or-obesity-100639041","NCT07595549","A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity","A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE-MONTHLY PF-08653944 IN ADULTS WITH OVERWEIGHT OR OBESITY (VESPER-6)","Inclusion Criteria:\n\n* Aged ≥18 years.\n* BMI of: ≥30 kg\u002Fm2 or ≥27.0 kg\u002Fm2 to \\\u003C30.0 kg\u002Fm2 and must have at least 1 of the following weight-related co-morbidities: hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease, or T2D.\n\nExclusion Criteria:\n\n* Have a self-reported body weight change greater than 5% within 90 days prior to Screening.\n* Diagnosis of type 1 diabetes or any other form of diabetes other than T2D.\n* History of acute or chronic pancreatitis.\n* Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN-2).",{"count":249,"type":22},954,[25],"The purpose of this clinical study is to learn about the effects and safety of berobenatide (PF-08653944). This may help people with overweight or obesity lose weight. People in this study may also have type 2 diabetes.\n\nAbout 950 adults will be in this study. Berobenatide will be compared to a placebo. A placebo does not have any medicine in it but looks just like the medicine being studied. Berobenatide or placebo is given by a shot under the skin in the belly area. The objective of the study is to compare the experiences of people receiving berobenatide to those of the people who do not to assess if the study medicine is effective and safe.\n\nPeople will take part in this study for about 20 months. During this time, they will have about 15 study visits at the site. They will also have 2 study visits over the phone.",[29,224,28],[226,227,101,79,229,254,255,256,28,29,228,257,258,259],"Diabetes Mellitus","Glucose Metabolism Disorders","Endocrine System Diseases","Signs and Symptoms","Pathological Conditions, Signs and Symptoms","Metabolic Diseases",{"date":181,"type":36},{"date":262,"type":36},"2026-06-10",{"date":264,"type":22},"2028-06-21",{"name":239,"class":43},38,{"id":268,"slug":269,"hasResults":12,"nctId":270,"briefTitle":271,"officialTitle":272,"acronym":273,"eligibilityCriteria":274,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":275,"targetDuration":4,"studyType":23,"phases":277,"briefSummary":278,"conditions":279,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":281,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":287},"100632101","phase-3-amaze-6-a-research-study-investigating-how-well-the-medicine-nnc0487-0111-helps-people-with-excess-body-weight-and-knee-osteoarthritis-lose-weight-and-reduce-pain-100632101","NCT07509307","AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain","Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Overweight or Obesity, and Knee Osteoarthritis (AMAZE 6)","AMAZE 6","Key Inclusion Criteria:\n\n* Male or female (sex at birth)\n* Age 18 years or above at the time of signing the informed consent\n* Clinical diagnosis of knee osteoarthritis (OA) (American College of Rheumatology criteria) with radiographic changes (Kellgren Lawrence \\[KL\\] grades 2 to 4 as per central reading) in target knee. Target knee joint is defined as most symptomatic knee at screening. If pain in knees is equal, the target knee joint will be the dominant leg\n* Symptomatic knee OA with first appearance of pain in the target knee \\> 90 days prior to screening and pain in the target knee for \\> 15 days over the prior 30 days\n* Willingness to complete a 72-hour washout period of analgesics before all visits involving WOMAC Osteoarthritis Index NRS 3.1 (24-hour) (WOMAC) questionnaire (acetaminophen 4 grams (g)\u002Fday is allowed as rescue medication up until 24 hours before those visits)\n\nKey Exclusion Criteria:\n\n* Glycated haemoglobin (HbA1c) ≥ 6.5% (48 mmol\u002Fmol) as measured by the central laboratory at screening\n* History of type 1 or type 2 diabetes mellitus as declared by the participant or reported in the medical records\n* Treatment with glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1\u002Fgastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment), or amylin analogues before screening\n* Any joint prosthesis or joint replacement in target knee\n* Arthroscopy or injections into target knee within the last 90 days prior to screening\n* Any other joint disease in target knee including gout and pseudogout",{"count":276,"type":22},400,[25],"This study is being done to look at the safety and effect of NNC0487-0111 in people with excess body weight and knee osteoarthritis when compared to placebo. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111, (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participants get is decided by chance.",[29,28,280],"Osteoarthritis, Knee",{"date":181,"type":36},{"date":283,"type":36},"2026-04-20",{"date":285,"type":22},"2028-08-14",{"name":209,"class":43},81,{"id":289,"slug":290,"hasResults":12,"nctId":291,"briefTitle":292,"officialTitle":293,"acronym":294,"eligibilityCriteria":295,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":296,"targetDuration":4,"studyType":23,"phases":298,"briefSummary":299,"conditions":300,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":302,"startDateStruct":303,"completionDateStruct":305,"leadSponsor":307,"locationsCount":308},"100652297","phase-3-research-study-on-how-well-oral-semaglutide-works-for-weight-loss-in-adults-with-excess-body-weight-100652297","NCT07770841","Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight","Efficacy and Safety of Once Daily Oral Semaglutide in Adults With Overweight or Obesity","OASIS 5","Inclusion Criteria:\n\n* Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.\n* Female or male (sex at birth).\n* Age 18 years or above at the time of signing the informed consent.\n* Body mass index (BMI) of\n\n  1. ≥ 27.0 kilogram per square meter (kg\u002Fm\\^2) with the presence of at least one weight-related comorbidity including, but not limited to, hypertension, dyslipidaemia, obstructive sleep apnoea or CV disease.\n\n     OR\n  2. ≥ 30.0 kg\u002Fm\\^2.\n* History of at least one self-reported unsuccessful dietary effort to lose body weight.\n\nExclusion Criteria:\n\n* A self-reported change in body weight greater than (\\>) 5% within 90 days before screening irrespective of medical records.\n* HbA1c ≥ 6.5% (48 millimoles per mole \\[mmol\u002Fmol\\]) as measured by the central laboratory at screening.\n* Consistent use of glucagon like peptide-1 (GLP-1) receptor agonists, including medication with glucagon like peptide-1 receptor agonist (GLP-1 RA) activity like dual GLP-1\u002Fgastric inhibitory peptide RAs, or amylin analogues before screening. Consistent use is defined as treatment.",{"count":297,"type":22},450,[25],"The purpose of this study is to see how oral semaglutide, when taken in lower doses help lowering of body weight in participants with excess body weight when compared to 'dummy' tablets (placebo). Results from this study will help select the most optimal lower dose of oral semaglutide that can be used for treating participants living with overweight or obesity.",[28,29],"2026-08-13",{"date":151,"type":36},{"date":304,"type":36},"2026-08-12",{"date":306,"type":22},"2028-04-11",{"name":209,"class":43},62,{"id":310,"slug":311,"hasResults":12,"nctId":312,"briefTitle":313,"officialTitle":314,"acronym":4,"eligibilityCriteria":315,"healthyVolunteers":12,"sex":18,"minAge":316,"maxAge":142,"enrollmentInfo":317,"targetDuration":4,"studyType":23,"phases":319,"briefSummary":321,"conditions":322,"keywords":324,"overallStatus":180,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":332,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":210},"100652163","acupoint-catgut-embedding-with-laser-acupuncture-for-weight-loss-in-adults-with-obesity-100652163","NCT07770893","Acupoint Catgut Embedding With Laser Acupuncture for Weight Loss in Adults With Obesity","Acupoint Embedding Combined With Laser Acupuncture for Obesity: A Randomized, Double-Blind, Sham Laser-Controlled Trial Evaluating Anthropometric, Biochemical, and Hemodynamic Outcomes","Inclusion Criteria:\n\n* Age 20 to 65 years\n* Body mass index of 27 kg\u002Fm\\^2 or greater, or body mass index of 24 kg\u002Fm\\^2 or greater together with a waist circumference of 90 cm or greater in men or 80 cm or greater in women\n* Able to fully understand the informed consent document and willing to give written informed consent\n* No use of weight-loss medication and no other weight-reduction treatment in the 3 months before enrollment\n* Willing to follow the dietary and exercise advice given during the trial\n\nExclusion Criteria:\n\n* Current use of medication that may affect body weight, including corticosteroids, antipsychotics, insulin, or glucagon-like peptide-1 (GLP-1) receptor agonists\n* Known secondary cause of obesity, such as hypothyroidism, Cushing syndrome, or pituitary disease\n* Severe cardiovascular, hepatic, or renal disease, or poorly controlled diabetes defined as glycated hemoglobin (HbA1c) above 9 percent\n* Currently pregnant, breastfeeding, or planning pregnancy within 6 months\n* Bariatric surgery within the previous 6 months\n* Known allergy to absorbable suture material\n* Skin infection at the embedding sites, keloid tendency, or coagulation disorder\n* Implanted cardiac pacemaker or other electromagnetic implant\n* Known photosensitivity disorder or current use of photosensitizing medication","20 Years",{"count":318,"type":22},120,[320],"NA","Acupoint catgut embedding and laser acupuncture have each been studied as treatments for obesity in adults, but the two have not been evaluated in combination, and few trials have measured anthropometric, biochemical, and blood pressure outcomes together.\n\nThis single-center randomized sham-controlled trial plans to enroll 120 adults aged 20 to 65 years with obesity. All participants receive the same acupoint catgut embedding with poliglecaprone 25 absorbable suture at 15 acupoints, comprising 25 insertions, once every 2 weeks for 6 sessions over 12 weeks. Participants are randomly assigned in a 1:1 ratio to receive, immediately before each embedding session, either active 810 nm laser acupuncture or sham laser acupuncture delivered with a device that is identical in appearance, indicator light, and operating sound but emits no therapeutic energy. Both groups also receive standardized dietary and exercise counseling.\n\nBecause the acupoint embedding regimen is identical in both groups and the groups differ only in whether the laser emits energy, the comparison estimates the incremental effect of laser acupuncture added to acupoint embedding. Participants are treated for 12 weeks and then followed for a further 12 weeks, to Week 24.",[29,323,28],"Obesity, Abdominal",[325,326,327,328,329,330,331],"acupoint catgut embedding","thread embedding acupuncture","laser acupuncture","photobiomodulation","poliglecaprone 25","traditional Chinese medicine","weight loss",{"date":151,"type":36},{"date":334,"type":22},"2026-09",{"date":336,"type":22},"2028-12",{"name":338,"class":339},"Taipei City Hospital","OTHER_GOV",{"id":341,"slug":342,"hasResults":12,"nctId":343,"briefTitle":344,"officialTitle":345,"acronym":346,"eligibilityCriteria":347,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":348,"targetDuration":4,"studyType":23,"phases":350,"briefSummary":351,"conditions":352,"keywords":355,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":356,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":360,"locationsCount":362},"100650045","phase-3-a-study-of-once-daily-oral-asc30-to-evaluate-the-efficacy-and-safety-in-adult-participants-with-obesity-or-overweight-with-type-2-diabetes-100650045","NCT07743450","A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes","A Phase III, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Once-Daily Oral ASC30 in Adult Participants With Obesity or Overweight With Type 2 Diabetes Mellitus (AURORA-2)","AURORA-2","Inclusion Criteria:\n\n1. Participant must be ≥18 years of age inclusive, or the legal age of consent in the jurisdiction in which the study is taking place at screening.\n2. Have a BMI ≥ 27 kg\u002Fm2 at screening.\n3. Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight.\n4. Have a diagnosis of T2D according to the WHO classification or other locally applicable standards, with HbA1c \\> 6.5% (48 mmol\u002Fmol) to ≤10.5% (91 mmol\u002Fmol) at screening.\n\nExclusion Criteria:\n\n1. Have Type 1 Diabetes Mellitus (T1DM), history of ketoacidosis or hyperosmolar state\u002Fcoma, or any other types of diabetes except T2DM.\n2. Have a self-reported change in body weight \\>5 kg (11 pounds) within 3 months prior to screening.\n3. Have an estimated glomerular filtration rate (eGFR) \\\u003C 15 mL\u002Fmin\u002F1.73 m2, as determined by the laboratory at screening.\n4. Have a history of acute or chronic pancreatitis any time prior to screening.\n5. Have known allergies or intolerance to glucagon-like peptide-1 Receptor Agonists (GLP-1 RA).\n6. Participants with a personal or family (first-degree relative) history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia (MEN) syndrome type 2.\n7. Are currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study.",{"count":349,"type":22},1560,[25],"Study ASC30-302 (AURORA-2) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance doses of once-daily oral ASC30 compared with placebo in participants with obesity or overweight and T2DM.",[29,28,353,354],"Chronic Weight Management","Type 2 Diabetes Mellitus",[29,28,79],{"date":202,"type":36},{"date":358,"type":22},"2026-08",{"date":40,"type":22},{"name":361,"class":43},"Ascletis Pharma (China) Co., Limited",136,{"id":364,"slug":365,"hasResults":12,"nctId":366,"briefTitle":367,"officialTitle":368,"acronym":369,"eligibilityCriteria":370,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":371,"targetDuration":4,"studyType":23,"phases":373,"briefSummary":374,"conditions":375,"keywords":376,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":378,"startDateStruct":379,"completionDateStruct":380,"leadSponsor":381,"locationsCount":318},"100649973","phase-3-a-study-of-once-daily-oral-asc30-to-evaluate-the-efficacy-and-safety-in-adult-participants-with-obesity-or-overweight-with-weight-related-comorbidities-100649973","NCT07743463","A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities","A Phase III, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Once-Daily Oral ASC30 in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (AURORA-1)","AURORA-1","Inclusion Criteria:\n\n1. Participant must be ≥18 years of age inclusive, or the legal age of consent in the jurisdiction in which the study is taking place at screening.\n2. Have a BMI ≥ 30 kg\u002Fm2 or a BMI ≥ 27 kg\u002Fm2 and presence of at least 1 of the following weight-related comorbidities (treated or untreated) at screening:\n\n   * Hypertension\n   * Dyslipidemia\n   * Obstructive sleep apnea\n   * Cardiovascular disease (for example, ischemic cardiovascular disease, New York Heart Association Functional Class I-III heart failure).\n3. Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight.\n\nExclusion Criteria:\n\n1. Have any prior diagnosis of diabetes mellitus (T1DM or T2DM), or any other types of diabetes, history of ketoacidosis, or hyperosmolar state\u002Fcoma. Participants with a history of gestational diabetes are eligible to participate in this trial.\n2. Have a self-reported change in body weight \\>5 kg (11 pounds) within 3 months prior to screening.\n3. Have an estimated glomerular filtration rate (eGFR) \\\u003C 15 mL\u002Fmin\u002F1.73 m2, as determined by the laboratory at screening.\n4. Have a history of acute or chronic pancreatitis any time prior to screening.\n5. Have known allergies or intolerance to other glucagon-like peptide-1 Receptor Agonists (GLP-1 RA) analogs.\n6. Participants with a personal or family (first-degree relative) history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia (MEN) syndrome type 2.\n7. Are currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study.",{"count":372,"type":22},3003,[25],"Study ASC30-301 (AURORA-1) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance doses of once-daily oral ASC30 compared with placebo in participants with obesity or overweight without T2DM.",[29,28,353],[29,28,377],"Weight Management",{"date":202,"type":36},{"date":358,"type":22},{"date":40,"type":22},{"name":361,"class":43},{"id":383,"slug":384,"hasResults":12,"nctId":385,"briefTitle":386,"officialTitle":387,"acronym":4,"eligibilityCriteria":388,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":389,"targetDuration":4,"studyType":23,"phases":390,"briefSummary":391,"conditions":392,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":394,"startDateStruct":395,"completionDateStruct":397,"leadSponsor":399,"locationsCount":401},"100644599","phase-3-a-study-to-evaluate-the-effects-of-enicepatide-in-participants-with-obesity-or-overweight-with-or-without-type-2-diabetes-100644599","NCT07670416","A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes","A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 in Adult Chinese Patients With Obesity or Overweight, With or Without Type 2 Diabetes Mellitus","Inclusion Criteria:\n\n* Body mass index (BMI) ≥24.0 kilograms per meter squared (kg\u002Fm\\^2) for participants with type 2 diabetes mellitus (T2DM)\n* BMI ≥28.0 kg\u002Fm\\^2 or BMI ≥24.0 and \\\u003C28.0 kg\u002Fm\\^2 and diagnosed with at least one weight-related comorbidity (prediabetes, hypertension, dyslipidemia, fatty liver, obstructive sleep apnea, or weight-related cardiovascular disease) for participants without T2DM\n* Agreement to adhere to the contraception requirements\n\nExclusion Criteria:\n\n* History of Type 1 diabetes mellitus (T1DM)\n* Obesity induced by other endocrinologic disorders\n* Any planned major medical procedure or surgery during the study\n* History of significant active or unstable major depressive disorder (MDD) or other severe psychiatric disorder\n* Any lifetime history of suicide attempt\n* History of any hematologic conditions that may interfere with HbA1c measurement\n* History of acute or chronic pancreatitis or clinically significant gallbladder disease\n* Treatment with any approved or investigational GLP-1-RA-based therapy within 6 months prior to randomization\n* Treatment with other investigational therapy within 3 months prior to randomization or less than 5 elimination half-lives prior to randomization, whichever is longer\n* Known allergy to any component of the study drug formulation or any other condition that is a contraindication to GLP-1 RAs or GLP-1\u002FGIP RAs",{"count":121,"type":22},[25],"The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon-like peptide-1 (GLP-1)\u002Fglucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA) being developed for chronic weight management, as an adjunct to a reduced-calorie diet and increased physical activity in participants without Type 2 diabetes mellitus (T2DM) who have obesity or overweight with at least one weight-related comorbidity, and in participants with T2DM who have obesity or overweight.",[29,28,393],"Type 2 Diabetes Mellitus (T2DM)",{"date":301,"type":36},{"date":396,"type":36},"2026-07-03",{"date":398,"type":22},"2028-03-15",{"name":400,"class":43},"Hoffmann-La Roche",18,{"id":403,"slug":404,"hasResults":12,"nctId":405,"briefTitle":406,"officialTitle":407,"acronym":4,"eligibilityCriteria":408,"healthyVolunteers":141,"sex":18,"minAge":19,"maxAge":409,"enrollmentInfo":410,"targetDuration":4,"studyType":23,"phases":412,"briefSummary":413,"conditions":414,"keywords":4,"overallStatus":180,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":416,"startDateStruct":417,"completionDateStruct":418,"leadSponsor":420,"locationsCount":158},"100652029","phase-1-a-first-in-human-research-study-on-how-nnc0721-8060-works-in-people-living-with-overweight-or-obesity-100652029","NCT07767175","A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or Obesity","A Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0721-8060 in Healthy Adult Participants Living With Overweight or Obesity","Inclusion Criteria:\n\n* Male or female (sex at birth).\n* Age 18-55 years (both inclusive) at the time of signing informed consent.\n* Body Mass Index (BMI) 27.0-34.9 kilograms per square metre (kg\u002Fm\\^2) (both inclusive) at screening, with overweight due to excess adipose tissue as judged by the investigator.\n* Considered eligible based on medical history, physical examination, vital signs, electrocardiogram and clinical laboratory tests at screening, as judged by the investigator.\n\nExclusion Criteria:\n\n* Known or suspected hypersensitivity to study intervention(s) or related products.\n* Previous randomisation in this study.\n* History of allergies (with the exception of seasonal allergies) or history of anaphylactic reactions.\n* Female who is pregnant, breastfeeding, intends to become pregnant, or is of childbearing potential and not using adequate contraception.\n* Current participation (signed informed consent) in any other interventional clinical study.\n* Exposure to an investigational medicinal product within 30 days or five half-lives of that product (whichever is longer) before screening.\n* Any disorder, unwillingness or inability which, in the investigator's opinion, might jeopardise participant safety or compliance with the protocol.\n* Glycated haemoglobin (HbA1c) greater than or equal to (≥) 6.5 percentage (%) (48 millimoles per mole \\[mmol\u002Fmol\\]) at screening.","55 Years",{"count":411,"type":22},142,[146],"The purpose of the study is to find out if NNC0721-8060 is safe and how it works in people living with overweight or obesity.",[28,29],"2026-08-11",{"date":181,"type":36},{"date":304,"type":22},{"date":419,"type":22},"2027-09-23",{"name":209,"class":43},{"id":422,"slug":423,"hasResults":12,"nctId":424,"briefTitle":425,"officialTitle":426,"acronym":4,"eligibilityCriteria":427,"healthyVolunteers":141,"sex":18,"minAge":19,"maxAge":142,"enrollmentInfo":428,"targetDuration":4,"studyType":23,"phases":430,"briefSummary":431,"conditions":432,"keywords":4,"overallStatus":180,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":433,"startDateStruct":434,"completionDateStruct":436,"leadSponsor":438,"locationsCount":439},"100651749","phase-1-a-study-of-macupatide-ly3532226-in-participants-with-obesity-or-overweight-without-type-2-diabetes-100651749","NCT07765511","A Study of Macupatide (LY3532226) in Participants With Obesity or Overweight Without Type 2 Diabetes","A Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Macupatide Monotherapy, and Macupatide in Combination With Eloralintide, in Japanese Participants With Obesity or Overweight Without Type 2 Diabetes.","Inclusion Criteria:\n\n* Are Japanese participants assigned male at birth (AMAB) or assigned female at birth (AFAB) who agree to contraception requirements or participants who are individuals not of childbearing potential (INOCBP).\n* Have a body mass index greater than or equal to (≥)25 kilograms per square meter (kg\u002Fm²)\n* Have had a stable weight for the 3 months prior to screening. Stable weight is defined as less than 5 percent (%) body weight change.\n\nExclusion Criteria:\n\n* Have known allergies to related compounds of macupatide or eloralintide, or any components of the formulations.\n* Have a history of significant atopy, including severe allergic manifestations, or clinically significant multiple or severe drug allergies, or severe posttreatment hypersensitivity reactions.\n* Have a history or presence of psychiatric disorders, including a history of major depressive disorder or severe psychiatric disorders, within the last 3 years, that would present a safety risk or may significantly impair the participant's ability to comply with study procedures.\n* Have been diagnosed with Type 1 or Type 2 diabetes mellitus.\n* Have a history of chronic medical conditions involving the heart, liver, or kidneys.\n* Have a history of any malignancy within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years.\n* Have a history or presence of a gastrointestinal (GI) disorder or previous surgery that impacts gastric emptying.\n* Have had or plan to have during the study, a device-based or surgical treatment use for obesity.\n* Have been treated, or plan to be treated, with prescription medications or other non approved drugs intended to promote weight loss, within 3 months prior to screening.\n* Are currently enrolled or have participated, within the last 30 days, in a clinical study involving an investigational product. If the previous investigational product has a long half-life, 5 half-lives or 30 days, whichever is longer, should have passed.\n* Have previously completed or withdrawn from this study or have previously received macupatide or eloralintide.\n* Have evidence of acute or chronic liver disease or pancreatic disease.",{"count":429,"type":22},60,[146],"The main purpose of this study is to assess how well macupatide, when dosed alone and in combination with eloralintide, is tolerated and what side effects may occur in participants with obesity or overweight without Type 2 diabetes. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. For each participant, the study will last about 4 months and will include 2 stays in the Clinical Research Unit (CRU), each lasting 3-5 nights.",[29,28],{"date":202,"type":36},{"date":435,"type":22},"2026-10",{"date":437,"type":22},"2027-06",{"name":42,"class":43},3,{"id":441,"slug":442,"hasResults":12,"nctId":443,"briefTitle":444,"officialTitle":445,"acronym":446,"eligibilityCriteria":447,"healthyVolunteers":12,"sex":18,"minAge":448,"maxAge":449,"enrollmentInfo":450,"targetDuration":4,"studyType":23,"phases":452,"briefSummary":454,"conditions":455,"keywords":461,"overallStatus":180,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":466,"startDateStruct":467,"completionDateStruct":469,"leadSponsor":471,"locationsCount":4},"100643950","early-phase-1-team-based-shared-decision-making-program-in-cardiovascular-kidney-metabolic-health-100643950","NCT07662616","Team-Based Shared Decision-Making Program in Cardiovascular-Kidney-Metabolic Health","Feasibility and Efficacy Pilot of a Team-Based Shared Decision-Making Program in Cardiovascular-Kidney-Metabolic Health, Medication Adherence, and Cardiovascular Health","SDM in CKM","Inclusion Criteria:\n\n* Are adults aged 30 to 79 years (to use PREVENT equations to calculate 10- and 30-year risk estimates for total CVD),\n* Are in stage 2 CKM: the presence of metabolic risk factors (hypertension \\[stages 1 and 2\\], hypertriglyceridemia \\[≥135 mg\u002FdL\\], diabetes, Metabolic Equivalents (MetS)\\*) and\u002For Chronic Kidney Disease (CKD) \\[moderate- to high-risk CKD which are stages 1-3 CKD\\]), and\n* Receive primary care at Johns Hopkins Community Physicians (JHCP).\n* Access to smart phone or tablet to use app.\n\nExclusion Criteria:\n\n* Have diagnosis of CVD,\n* Stage 4-5 CKD, kidney failure, or on dialysis\n* Have a serious medical condition such as cancer;\n* On or planning to start Glucagon-like peptide-1 (GLP-1) receptor agonists in next 6 months;\n* Have cognitive impairment;\n* Are currently involved in other programs on improving LE8; or\n* Unwillingness to provide informed consent\n* Unable to speak, read, or communicate in English.","30 Years","79 Years",{"count":451,"type":22},94,[453],"EARLY_PHASE1","The investigators are proposing a new team-based shared decision-making (SDM) program. The goal of this study is to see whether this program is practical and whether it may help adults with cardiometabolic risk factors and cardiovascular-kidney-metabolic syndrome. The investigators will enroll adults from a primary care clinic in Maryland. People in the intervention group will take part in the 6-month program in addition to usual care. People in the control group will receive usual care only.",[456,457,458,459,29,460,28],"Hypertension (HTN)","Diabetes (DM)","Hyperlipidaemia","Kidney Disease","Cardiovascular-kidney-metabolic (CKM)",[462,463,464,465],"shared decision-making","Cardiovascular-kidney-metabolic","Behavioral counseling","Team-based care",{"date":304,"type":36},{"date":468,"type":22},"2026-09-10",{"date":470,"type":22},"2028-06-30",{"name":472,"class":473},"Johns Hopkins University","OTHER",{"id":475,"slug":476,"hasResults":12,"nctId":477,"briefTitle":478,"officialTitle":479,"acronym":480,"eligibilityCriteria":481,"healthyVolunteers":12,"sex":482,"minAge":19,"maxAge":4,"enrollmentInfo":483,"targetDuration":4,"studyType":23,"phases":485,"briefSummary":486,"conditions":487,"keywords":492,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":496,"startDateStruct":497,"completionDateStruct":498,"leadSponsor":500,"locationsCount":158},"100608263","the-preeclampsia-postpartum-prevention-trial-100608263","NCT07199283","The PreEclampsia Postpartum Prevention Trial","The PEPP Trial: A Postpartum Bundle Intervention to Improve Cardiometabolic Health in Women After a First Pregnancy Affected by Preeclampsia - a Multi-centre Randomised Controlled Trial","PEPP","Inclusion Criteria\n\n* First-time mothers postpartum\n* Preeclampsia during first pregnancy\n* Age ≥ 18 years\n* Singleton live birth (infant still alive)\n* Ability to understand and speak Swedish, English\n* Having a smartphone (Android or iOS)\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Pre-pregnancy hypertension\n* Diabetes mellitus type I or II\n* Cardiovascular disease\n* Kidney disease\n* Systemic lupus erythematosus\n* Antiphospholipid syndrome\n* Previous or current eating disorders\n* Ongoing new pregnancy","FEMALE",{"count":484,"type":22},356,[320],"The goal of this clinical trial is to learn if a postpartum bundle intervention can improve cardiometabolic health and lifestyle-related factors in women who have had preeclampsia during their first pregnancy. The main questions it aims to answer are:\n\n* Does the 9-month intervention reduce systolic and diastolic blood pressure?\n* Does the intervention promote postpartum weight loss?\n* Does the intervention affect weight and blood pressure depending on early pregnancy BMI? Researchers will compare the bundle intervention to standard care to see if the intervention improves cardiometabolic health and lifestyle outcomes.\n\nAll participants will attend clinical visits for outcome assessments.\n\nParticipants in the intervention group will:\n\n* Receive online targeted screening and group meetings with study personnel\n* Use the trial-specific PEPP app to access self-monitoring tools for blood pressure and weight, lifestyle modification, and health education\n* Follow the intervention in two phases: starting after inclusion (≈8 weeks postpartum) with a Light phase (baseline-3 months) and progressing to an Intensive phase (3-9 months)",[488,489,490,491,28,29],"Preeclampsia","Postpartum Period","Hypertension","Cardiovascular Diseases",[488,493,494,490,495],"Postpartum prevention","Prevention cardiometabolic disease","Postpartum weight loss",{"date":304,"type":36},{"date":283,"type":36},{"date":499,"type":22},"2028-04",{"name":501,"class":473},"Karolinska Institutet",{"id":503,"slug":504,"hasResults":12,"nctId":505,"briefTitle":506,"officialTitle":507,"acronym":4,"eligibilityCriteria":508,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":509,"targetDuration":4,"studyType":23,"phases":510,"briefSummary":511,"conditions":512,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":513,"lastUpdatePostDateStruct":514,"startDateStruct":515,"completionDateStruct":517,"leadSponsor":519,"locationsCount":158},"100651146","phase-1-a-research-study-to-see-how-nnc0487-0111-affects-the-bodys-energy-use-after-a-weight-loss-in-adults-living-with-obesity-compared-to-a-low-calorie-diet-or-placebo-100651146","NCT07757087","A Research Study to See How NNC0487-0111 Affects the Body's Energy Use After a Weight Loss in Adults Living With Obesity, Compared to a Low-calorie Diet or Placebo","The Effect of Once-weekly Subcutaneous NNC0487-0111 Compared to an Energy-restricted Diet or Placebo on Energy Metabolism in Adults Living With Obesity: a Randomised, Placebo-controlled Study","Inclusion Criteria:\n\n* Male or female (sex assigned at birth, inclusive of all gender identities).\n* Age 18 years or older at the time of signing the informed consent.\n\nExclusion Criteria:\n\n* Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using highly effective contraceptive method.\n* Exposure to an investigational medicinal product before screening.\n* Any condition, or disorder, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.\n* Anticipated change in lifestyle (e.g., eating, exercise or sleeping pattern) during the study, for example, an imminent job change to\u002Ffrom a physically demanding occupation.\n* Claustrophobia or severe discomfort of being confined in small rooms.\n* History of type 1 or type 2 diabetes mellitus.\n* Presence or history of any clinically relevant respiratory, metabolic, renal, hepatic, cardiovascular, gastrointestinal (GI), or endocrinological conditions.\n* Unusual meal habits (including, but not limited to, eating disorders) and special diet requirements or unwillingness to eat the food provided in the study.\n* Use of any weight lowering pharmacotherapy or pharmacotherapy that may cause weight gain, including systemic corticosteroids (except for a short course of treatment, i.e., 7-10 days), tri-cyclic antidepressants, atypical antipsychotic and mood stabilisers prior to screening.\n* Use of incretin or amylin-based therapies prior to screening or previous discontinuation of long-term incretin and\u002For amylin-based therapy due to tolerability issue.\n* Physical activity of moderate to vigorous intensity for greater than (\\>) 4 hours\u002Fweek within the past 6 months before screening.",{"count":318,"type":22},[146],"The purpose of this clinical study is to evaluate how NNC0487-0111 affects the amount of energy the body uses in people living with obesity following weight loss. This will be compared with the amount of energy used by participants who achieve weight loss through a low-calorie diet and by participants receiving placebo (without weight loss).",[28,29],"2026-08-10",{"date":415,"type":36},{"date":516,"type":36},"2026-08-03",{"date":518,"type":22},"2028-09-18",{"name":209,"class":43},{"id":521,"slug":522,"hasResults":12,"nctId":523,"briefTitle":524,"officialTitle":525,"acronym":526,"eligibilityCriteria":527,"healthyVolunteers":12,"sex":18,"minAge":528,"maxAge":142,"enrollmentInfo":529,"targetDuration":4,"studyType":23,"phases":530,"briefSummary":531,"conditions":532,"keywords":535,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":513,"lastUpdatePostDateStruct":542,"startDateStruct":543,"completionDateStruct":545,"leadSponsor":547,"locationsCount":210},"100648849","digital-dietary-intervention-for-patients-receiving-glp-1-receptor-agonist-therapy-100648849","NCT07728669","Digital Dietary Intervention for Patients Receiving GLP-1 Receptor Agonist Therapy","Efficacy of a Digital Dietary Intervention (NutriSteppe Application) in Improving Metabolic Parameters in Adults With Type 2 Diabetes Mellitus, Obesity or Overweight With Comorbidities Who Are Receiving GLP-1 Receptor Agonist Therapy and Other Medications Prescribed Under Routine Clinical Protocols","NutriSteppe","Inclusion Criteria:\n\n* Age 21-65 years inclusive at the time of signing informed consent.\n* Male or female.\n* Overweight with at least one comorbidity, including diabetes mellitus; arterial hypertension of at least 130\u002F85 mmHg or use of antihypertensive medication; dyslipidemia defined as triglycerides of at least 1.7 mmol\u002FL, reduced HDL cholesterol below 1.0 mmol\u002FL in men or below 1.3 mmol\u002FL in women, or use of lipid-lowering medication; cardiovascular disease; respiratory or joint disease; non-alcoholic fatty liver disease; sleep disorders; or other comorbidities.\n* For participants with overweight: body mass index of 25.0-29.9 kg\u002Fm² for the Caucasian population or 23.0-27.4 kg\u002Fm² for the Asian population, together with abdominal obesity defined as waist circumference of at least 94 cm in men and 80 cm in women of the European population, or at least 90 cm in men and 80 cm in women of the Asian population.\n* Class I-III obesity where diet combined with physical activity has been ineffective, defined as weight loss of less than 5% over 3 months.\n* Class I obesity: body mass index of 30.0-34.9 kg\u002Fm² for the Caucasian population or 27.5-32.4 kg\u002Fm² for the Asian population.\n* Class II obesity: body mass index of 35.0-39.9 kg\u002Fm² for the Caucasian population or 32.5-37.4 kg\u002Fm² for the Asian population.\n* Type 2 diabetes mellitus with HbA1c of at least 6.5% (48 mmol\u002Fmol), fasting glucose of at least 6.1 mmol\u002FL in capillary whole blood or at least 7.0 mmol\u002FL in venous plasma, glucose of at least 11.1 mmol\u002FL two hours after an oral glucose tolerance test, or random glucose of at least 11.1 mmol\u002FL.\n* Body mass index of at least 25 kg\u002Fm² and no more than 40 kg\u002Fm² at screening.\n* Already receiving, or prescribed, GLP-1 receptor agonist therapy with semaglutide by the treating physician independently of the study. The study does not prescribe or modify this therapy.\n* Stable doses of medications for chronic conditions, including antihypertensive agents and statins, for at least 8 weeks before screening.\n* Ownership of an iOS or Android smartphone with internet access and willingness to download and use the \"NutriSteppe\" application if assigned to the intervention group.\n* Ability and willingness to provide written informed consent and comply with study procedures.\n* Women of childbearing potential must use effective contraception throughout the study.\n\nExclusion Criteria:\n\n* Diagnosis of type 1 diabetes mellitus.\n* History of diabetic ketoacidosis or hyperglycemic hyperosmolar state.\n* Initiation of GLP-1 receptor agonist therapy less than 4 weeks before screening.\n* Current insulin therapy.\n* Personal or family history of medullary thyroid carcinoma.\n* Personal history of multiple endocrine neoplasia type 2 (MEN2).\n* History of acute or chronic pancreatitis.\n* Active gallbladder disease or history of gallbladder disease within 6 months before screening.\n* Severe gastrointestinal disease, including gastroparesis.\n* Major cardiovascular event within 6 months before screening, including myocardial infarction, stroke, transient ischemic attack, unstable angina, coronary artery bypass grafting, or percutaneous coronary intervention.\n* Uncontrolled arterial hypertension, defined as systolic blood pressure above 160 mmHg or diastolic blood pressure above 100 mmHg at screening.\n* Chronic kidney disease with an estimated glomerular filtration rate below 30 mL\u002Fmin\u002F1.73 m² using the MDRD or CKD-EPI formula.\n* Severe hepatic impairment classified as Child-Pugh class C, or ALT or AST greater than three times the upper limit of normal.\n* Active malignancy or history of malignancy within 5 years, except successfully treated basal cell or squamous cell carcinoma of the skin.\n* Established HIV infection, active hepatitis B defined as HBsAg positive with detectable HBV DNA, or hepatitis C virus infection.\n* History of bariatric surgery or bariatric surgery planned during the study.\n* Anorexia nervosa, bulimia nervosa, or binge eating disorder diagnosed or active within the past year.\n* Pregnancy or breastfeeding.\n* Planning pregnancy during the study.\n* Woman of childbearing potential unwilling to use effective contraception.\n* Use of weight-loss medication, including orlistat, phentermine, combinations with topiramate, naltrexone-bupropion, or other weight-loss medication within 3 months before screening.\n* Use of systemic corticosteroids, excluding inhaled or topical corticosteroids, for more than 2 weeks within 3 months before screening.\n* Use of antipsychotic medication associated with significant weight gain unless used at a stable dose for more than 6 months.\n* Participation in another interventional clinical study within 30 days before screening.\n* Known hypersensitivity to semaglutide or any excipient.\n* No smartphone or unwillingness to use digital health technology.\n* Severe mental disorder impairing the ability to provide informed consent or comply with the protocol.\n* Active alcohol or drug dependence within the past year.\n* Any condition that, in the investigator's opinion, may compromise participant safety or the integrity of the study.","21 Years",{"count":318,"type":22},[320],"The goal of this clinical trial is to learn whether adding the NutriSteppe digital dietary intervention to routine medical care improves metabolic health in adults aged 21 to 65 years with type 2 diabetes mellitus, obesity, or overweight with related health conditions. Participants are already receiving or have been prescribed glucagon-like peptide-1 (GLP-1) receptor agonist therapy by their treating physicians outside the study.\n\nThe main question is:\n\nDoes the NutriSteppe digital dietary intervention improve glycated hemoglobin (HbA1c), a measure of average blood glucose, after 12 weeks compared with routine medical care alone?\n\nThe study will also assess changes in fasting blood glucose, body weight, body mass index, waist circumference, cholesterol, triglycerides, blood pressure, diet quality, quality of life, dietary adherence, and safety.\n\nResearchers will randomly assign participants to one of two groups. The control group will continue routine medical care and receive general lifestyle advice. The intervention group will continue routine medical care and use the NutriSteppe application for 12 weeks to receive personalized dietary support.\n\nParticipants in both groups will:\n\n* Attend study visits and complete the examinations, laboratory tests, and questionnaires specified in the study protocol.\n* Photograph everything they eat and drink.\n* Have their food photographs automatically analyzed using Tagam-AI, a system developed for this study.\n* Be able to view the results of the food photograph analysis.\n\nThe photography and automated analysis procedures will be the same in both groups. Only participants in the intervention group will receive personalized dietary recommendations generated from these data through the NutriSteppe application.",[393,533,28,534],"Obesity (Disorder)","Metabolic Syndrome",[526,536,537,538,539,540,541],"Digital Dietary Intervention","Personalized Nutrition","GLP-1 Receptor Agonist","Semaglutide","Glycated Hemoglobin","HbA1c",{"date":415,"type":36},{"date":544,"type":36},"2026-07-20",{"date":546,"type":22},"2027-01",{"name":548,"class":473},"Kazakh Academy of Nutrition",{"id":550,"slug":551,"hasResults":12,"nctId":552,"briefTitle":553,"officialTitle":554,"acronym":4,"eligibilityCriteria":555,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":449,"enrollmentInfo":556,"targetDuration":4,"studyType":23,"phases":558,"briefSummary":559,"conditions":560,"keywords":561,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":569,"lastUpdatePostDateStruct":570,"startDateStruct":571,"completionDateStruct":573,"leadSponsor":575,"locationsCount":577},"100641707","efficacy-and-safety-of-aleniglipron-in-participants-with-obesity-or-overweight-with-a-weight-related-comorbidity-accomplish-1-100641707","NCT07654361","Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)","A Randomized, Double-Blind, Placebo-Controlled, Pivotal Phase 3 Study to Evaluate the Long-Term Efficacy and Safety of Multiple Maintenance Doses of Once Daily Oral Aleniglipron for Chronic Weight Management in Adults With Obesity or Overweight and a Weight-Related Comorbidity","Inclusion Criteria:\n\n* Signed informed consent\n* BMI ≥30 kg\u002Fm2 (obese) or BMI ≥27 kg\u002Fm2 (overweight) and presence of ≥1 of the obesity related comorbidities.\n\nExclusion Criteria:\n\n* Previously documented diagnosis of type 1 diabetes, type 2 diabetes, or any other type of diabetes.\n* Self-reported change in body weight \\>5 kg within 3 months before Screening.\n* Have prior or planned surgical or non-surgical treatment for obesity.\n* Have or plan to have endoscopic and\u002For device-based therapy for obesity.\n* Have obesity induced by other endocrine disorders.\n* Impaired renal function at Screening\n* Chronic malabsorption",{"count":557,"type":22},3600,[25],"Study GSBR-1290-12 is a Phase 3 pivotal, multicenter, global, randomized, placebo-controlled, double-blind study to investigate the long-term efficacy, safety, and tolerability of 3 maintenance doses of aleniglipron once daily (QD) compared with placebo, when used in combination with a reduced-calorie diet and increased physical activity. All participants will be randomized to at least 76 weeks of treatment to evaluate the effects on long term body weight changes, tolerability, and safety. In addition, the study will compare the effects between aleniglipron and placebo on blood pressure (BP), lipid parameters, patient-reported outcomes.",[29,28,353],[29,28,562,563,564,565,566,567,568],"GSBR-1290","Aleniglipron","Chronic weight management","Obese","Small molecule","GLP-1","Structure Therapeutics","2026-08-07",{"date":513,"type":36},{"date":572,"type":36},"2026-07-13",{"date":574,"type":22},"2028-11",{"name":576,"class":43},"Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics",71,{"id":579,"slug":580,"hasResults":12,"nctId":581,"briefTitle":582,"officialTitle":583,"acronym":4,"eligibilityCriteria":584,"healthyVolunteers":141,"sex":18,"minAge":19,"maxAge":449,"enrollmentInfo":585,"targetDuration":4,"studyType":23,"phases":587,"briefSummary":588,"conditions":589,"keywords":591,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":569,"lastUpdatePostDateStruct":599,"startDateStruct":600,"completionDateStruct":602,"leadSponsor":603,"locationsCount":604},"100641426","a-study-of-aleniglipron-in-adults-with-obesity-or-overweight-and-type-2-diabetes-mellitus-accomplish-2-100641426","NCT07654374","A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)","A Long-Term Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Multiple Maintenance Doses of Oral Once Daily Aleniglipron for Chronic Weight Management in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)","Inclusion Criteria:\n\n* Signed Informed Consent\n* Have a BMI ≥27.0 kg\u002Fm2 at Screening\n* Have a diagnosis of T2DM according to the WHO classification or other locally applicable standards, with HbA1c ≥6.5% (≥53 mmol\u002Fmol) to ≤10% (86 mmol\u002Fmol) at Screening\n\nExclusion Criteria:\n\n* Have type 1 diabetes, history of ketoacidosis or hyperosmolar state\u002Fcoma, or any other types of diabetes except T2DM.\n* Have had 1 or more episode of severe hypoglycemia and\u002For 1 or more episode of hypoglycemia unawareness within 180 days prior to Screening.\n* Are currently receiving or planning to receive treatment for diabetic retinopathy and\u002For macular edema\n* Self-reported change in body weight \\>5 kg (11 pounds) within 3 months before Screening.\n* Have prior or planned surgical or non-surgical treatment for obesity.",{"count":586,"type":22},1100,[25],"This is randomized, double-blind, placebo-controlled study of the long-term efficacy, safety, and tolerability of multiple doses of aleniglipron in participants living with overweight or obesity and T2DM. Participants will be randomized to aleniglipron or placebo for a total of 76 weeks of treatment.",[29,28,353,590],"Type2 Diabetes Mellitus",[592,593,562,594,595,596,597,598,567,568],"obesity","overweight","aleniglipron","chronic weight management","obese","type 2diabetes mellitus","small molecule",{"date":513,"type":36},{"date":601,"type":36},"2026-07-17",{"date":574,"type":22},{"name":576,"class":43},74,{"id":606,"slug":607,"hasResults":12,"nctId":608,"briefTitle":609,"officialTitle":610,"acronym":4,"eligibilityCriteria":611,"healthyVolunteers":141,"sex":18,"minAge":19,"maxAge":612,"enrollmentInfo":613,"targetDuration":4,"studyType":23,"phases":615,"briefSummary":616,"conditions":617,"keywords":618,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":569,"lastUpdatePostDateStruct":621,"startDateStruct":622,"completionDateStruct":624,"leadSponsor":626,"locationsCount":210},"100638165","phase-1-a-trial-of-oral-vrb-103-alone-or-in-combination-with-oral-ecnoglutide-vrb-101-in-participants-with-obesity-or-overweight-100638165","NCT07628127","A Trial of Oral VRB-103 Alone or in Combination With Oral Ecnoglutide (VRB-101) in Participants With Obesity or Overweight","A Randomized, Double-blind, Placebo-controlled, First-in-Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral VRB-103 Alone or in Combination With Oral Ecnoglutide (VRB-101) in Participants With Obesity or Overweight","Inclusion Criteria:\n\n1. Male or female assigned at birth, inclusive of all gender identities.\n2. Have HbA1c ≤6.4% at Screening and Day -2 eligibility confirmation.\n3. Have a BMI of:\n\n   1. ≥25 kg\u002Fm\\^2 and ≤35.0 kg\u002Fm\\^2 (Part A) OR\n   2. ≥27 kg\u002Fm\\^2 and ≤40.0 kg\u002Fm\\^2 (Part B and Part C)\n4. Weight ≥70 kg with self-reported stable body weight (≤5% body weight change) for the 3 months prior to randomization.\n5. Otherwise healthy, as defined by the absence of any clinically significant, in the Investigator's opinion, active or chronic disease (e.g., Type 2 diabetes mellitus \\[T2DM\\], cardiovascular \\[CV\\] disease, cancer, and any acute or chronic illness that could pose a problem to completing the study) as determined through a comprehensive medical and surgical history, a thorough physical exam (PE) that includes vital signs, a 12-lead Electrocardiogram (ECG), hematology, blood chemistry, serology, and urinalysis. Cardiovascular (CV) risk factors, such as dyslipidemia and mild hypertension, are expected and are allowed.\n6. Have an estimated glomerular filtration rate (eGFR) \\>60 mL\u002Fmin at Screening and Day -2 eligibility confirmation, as calculated using the 2021 Chronic Kidney Disease Epidemiology (CKD-EPI) creatinine equation, with no other clinical or laboratory evidence of renal dysfunction or impairment.\n7. Persons of childbearing potential must be non-pregnant and non-lactating and must agree to use study-specified contraceptive methods.\n8. Have a resting BP of ≤140\u002F90 millimeters of mercury (mmHg) at Screening and Day -2 eligibility with 2 or less hypertension-directed medications.\n\nExclusion Criteria:\n\n1. Have any prior diagnosis of type 1 diabetes mellitus or T2DM, or other forms of diabetes mellitus. A participant with a history of gestational diabetes may be included in the study if the participant has HbA1c ≤6.4% at Screening and Day -2 eligibility confirmation and is not on medication to lower glucose.\n2. Have at least 1 laboratory value suggestive of diabetes at Screening and Day -2 eligibility confirmation, including 1 or more of HbA1c \\>6.4% (48 mmol\u002Fmol) or random glucose ≥200 mg\u002FdL (11.1 mmol\u002FL).\n3. Have had exposure to GLP-1, glucose-dependent insulinotropic peptide (GIP), or amylin analogs within 6 months prior to Screening or any prior history of known or suspected hypersensitivity\u002Fallergies, intolerability, or lack of efficacy to these medications. Have known or suspected hypersensitivity to study product(s), to amylin analogs, to selective GLP-1 receptor agonist (RAs), or to GIP\u002FGLP-1 or GLP-1\u002Fglucagon dual RAs.\n4. Presence or history of clinically significant cardiovascular, renal, hepatic, dermatological, respiratory, neurological, psychiatric, malignant, metabolic, endocrinological, hematological, or venereal disorder, as judged by the Investigator.\n5. Have a medical history of clinically significant gastric emptying abnormality (for example, severe gastroparesis or gastric outlet obstruction), chronically take drugs that directly affect gastrointestinal (GI) motility, or have a history of any clinically relevant GI diseases or symptoms of GI disorders potentially affecting interpretation of study data.\n6. Have a history of hypocalcemia or ionized serum calcium below the normal range at Screening and Day -2 eligibility confirmation.","60 Years",{"count":614,"type":22},336,[146],"The primary objective is to evaluate the safety and tolerability of VRB-103 tablets administered as monotherapy or VRB-103 tablets administered in combination with oral ecnoglutide tablets (VRB-101 tablets) in a single-dose regimen or in a multiple dose regimen.",[29,28],[619,620],"Glucagon-like peptide-1 (GLP-1)","Recombinant human amylin analog",{"date":415,"type":36},{"date":623,"type":36},"2026-07-06",{"date":625,"type":22},"2028-03",{"name":627,"class":43},"Verdiva Bio Dev Limited"]